Callisto Pharmaceuticals Inc.: Buy -------------> bald doch 5 Dollar - 500 Beiträge pro Seite

[js200]

Die Analysten von Stanford Research bewerten in ihrer Analyse vom Freitag, 22. April 2005 die Aktie von Callisto Pharmaceuticals Inc. neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 5 $.

JS200

[js200]

Web Alert: Biophan Technologies, Callisto Pharmaceuticals, MIV Therapeutics and Xenomics to Present at Trilogy Capital`s Biotechnology Forum Tues, Oct. 11th at Noon ET

Monday , October 10, 2005 03:30 ET

LOS ANGELES, Oct 10, 2005 (PRIMEZONE via COMTEX) --Key executives and spokespersons from emerging growth smallcap companies Biophan Technologies (OTCBB:BIPH), Callisto Pharmaceuticals (AMEX:KAL), MIV Therapeutics (OTCBB:MIVT) and Xenomics (OTCBB:XNOM) will present strategic overviews and other investor-specific background in an online webcast of Trilogy Capital Partners` Biotechnology Forum, scheduled to start at 12 noon Eastern, October 11, 2005.

The Forum will also feature a keynote address from Dan D`Agostino, an investment banker who has specialized in the biotechnology sector for approximately 20 years. His address will focus on the current climate for biotechnology investment, including an analysis of sector performance during the second and third quarter of 2005. The conference will also feature brief comments by Paul Karon, President of Trilogy Capital Partners.

The webcast will last approximately 30 minutes. To view the conference, register online as explained below. There is no charge to register or watch the Forum. Conference and webcast information is as follows:


What: This live over-the-Internet video presentation employs a
fast-moving, informative format. It features on-camera
presentations by CEOs and company presenters, with
informational slides.

Who: Conference Moderator: Paul Karon, President - Trilogy
Capital Partners, Inc. Keynote Speaker: Dan Dagastino.
Participating companies: MIV Therapeutics (OTCBB:MIVT),
Callisto Pharmaceuticals (AMEX:KAL), Xenomics (OTCBB:XNOM)
and Biophan Technologies (OTCBB:BIPH) will participate.

When: Tuesday, October 11, 2005, at Noon Eastern.

Where: Please register at www.trilogy-capital.com. Simply log
on a few minutes before the start of the Forum and you
will be able to view the webcast. Refresh your browser
if video fails to initiate or viewing difficulties occur.

Cost: The conference is free of charge and open to all
interested investors.

Archive: If you are unable to view the initial webcast, the
Forum will be archived for replay at
http://www.trilogy-capital.com.

Contact: Paul Karon at [phone] or
[e-mail].


About the Companies:

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA`s Ames Center for Nanotechnology. Biophan`s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol BTN. For more information, please visit www.biophan.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in preclinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus. Callisto`s two lead anti-cancer products include Annamycin, a novel liposomal drug from the anthracycline family with potentially reduced cardiotoxicity, a patented liposomal formulation, and the potential to circumvent multi-drug resistance in both ALL and AML; and Atiprimod, a small-molecule oral drug with a potential multiplicity of effects, including tumor cell anti-proliferative and anti-angiogenic activities to treat relapsed multiple myeloma (MM). Atiprimod is presently in a Phase I/IIa clinical trial in relapsed or refractory MM patients at four clinical sites in the U.S. In addition to cancer treatments, Callisto is developing a drug pre-clinically for treatment of inflammatory bowel disease (IBD). Callisto also has received a major biodefense partnership grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a monoclonal antibody and vaccine against bacterial superantigen toxins. Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company`s ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company`s unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company`s novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company`s drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics` Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is also traded on the Frankfurt Stock Exchange under the ticker symbol MIV.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics` patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company`s Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company`s next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html. Xenomics is listed on the Frankfurt Stock Exchange under the symbol XE7.

About Trilogy Capital Partners

Trilogy Capital Partners is a Los Angeles-based financial services company engaged in merchant banking, strategic planning, financial marketing and communications. Based on the simple concept that many well-run public companies are not realizing their full value in the marketplace, Trilogy has aggregated highly experienced executives into a formidable financial and marketing team, which help investors identify and maximize prospective high-return opportunities. Trilogy is committed to identifying companies with strong management, a compelling business model and, most importantly, companies that may be seriously undervalued. For more information on Trilogy or its portfolio companies, please visit www.trilogy-capital.com.

This news release was distributed by PrimeZone, www.primezone.com

SOURCE: Trilogy Capital Partners, Inc.

Trilogy Capital Partners, Inc.
Paul Karon
[phone]
[e-mail]

(C) 2005 PRIMEZONE, All rights reserved.

[js200]

Last Trade: 1.530 Change: 0.040 (+2.685%)
Previous Close: 1.490 Volume: 71,300
Bid: N/A Ask: N/A
Today`s Open: 1.490 # of Trades: 26

[TerrySam]

Börse
NASDAQ OTC BB
Lamp
Aktuell
0,02 USD

Zeit
10.10.05 20:12

Diff. Vortag
-4,76 %

Tages-Vol.
3.190,70

Gehandelte Stück
161.800

War es der Sache wert??????????????????????????????

[JAY25]

[posting]18.220.184 von TerrySam am 10.10.05 23:52:30[/posting]Und seine Lampies wo wir einen riesen Verlust gemacht haben!

[js200]

10/21/2005 (12:37 ET) KAL: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/21/2005 (12:17 ET) Callisto CEO Details Recent Progress and Outlook to Achieve Strategic Goals at Annual Shareholder Meeting; CEO Cites Strategic Initiatives to Develop New Drugs to Treat Serious Forms of Cancer and Other Conditions - Business Wire
10/21/2005 (10:22 ET) KAL: Filed New Form 8-K, Material Event Disclosure - Edgar
10/21/2005 (06:00 ET) KAL: Short Interest DN 86.8% to 764 in Oct 2005 - Knobias
10/20/2005 (16:15 ET) KAL: Short Interest DN 86.8% to 764 in Oct 2005 - Knobias

[ladilla]

wo hast du diese infos her und was bedeutet das in deutschem klartext??? danke fuer eine ausfuehrung

[conejo2222]

Callisto`s Drug Development Achievements to be Spotlighted at Rodman & Renshaw Techvest Healthcare Investor Conference; Company to Present Latest Clinical and Drug Development Milestones for Institutional Investors and Biotech Community



NEW YORK--(BUSINESS WIRE)--Nov. 2, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against hematological cancers and other diseases, will present recent milestones and initiatives at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City, a high-profile forum for institutional investors and other professionals in the worldwide biotechnology industry.

Dr. Donald Picker, Executive Vice President of R&D, will highlight Callisto`s key proprietary technology assets during a session scheduled for Wednesday, November 9, at 10:30 a.m., in the Kennedy II Salon of the New York Palace Hotel. The conference is scheduled for November 7-9.

"We will provide an overview of our Company`s drug development programs, including the hematological oncology markets our drug candidates are designed to address," Dr. Picker said. "Callisto`s current drug development programs include Atiprimod, a new treatment for the blood cancer multiple myeloma, and L-Annamycin, a drug designed to treat forms of leukemia. We are also developing drugs for gastrointestinal inflammation, and we have an ongoing program to develop drugs to protect against biowarfare agents for use in homeland security applications. In addition, we will review Callisto`s strategic goals for 2006."

The Rodman & Renshaw Techvest healthcare conferences are designed to attract institutional investors, venture capitalists, private investors, business development professionals and other investment professionals.

About Rodman & Renshaw

Rodman & Renshaw is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research and the development of institutional support. During the last two years, Rodman & Renshaw completed over 75 financing transactions, totaling over $1.2 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors. More information is available at www.rodmanandrenshaw.com.

About Callisto Pharmaceuticals, Inc.


Callisto is a biopharmaceutical company focused on the development
of new drugs to treat various forms of cancer and other serious
afflictions. Callisto`s drug candidates in development currently
include anti-cancer agents in clinical development, in addition to
drugs for a range of other significant health care market segments,
including biodefense. One of the Company`s lead drug candidates,
L-Annamycin, is being developed as a treatment for forms of relapsed
leukemia, a currently incurable blood cancer. Callisto intends to
initiate a clinical trial of L-Annamycin in relapsed acute
lymphoblastic leukemia patients in 4Q 2005. L-Annamycin, a new
compound from the anthracycline family of proven anti-cancer drugs,
has a novel therapeutic profile, including activity against resistant
diseases and significantly reduced cardiotoxicity, or damage to the
heart, compared to currently available drug alternatives. Another
anti-cancer drug, Atiprimod, is in development to treat relapsed
multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa
human clinical trials in relapsed multiple myeloma patients. Callisto
also has drugs in preclinical development for gastrointestinal
inflammation, and a program focused on the development of a drug to
protect against staphylococcus and streptococcus biowarfare agents.
Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D.
Anderson Cancer Center to develop, manufacture, use and sell Atiprimod
and L-Annamycin, respectively. For investor-specific information about
Callisto, including recent news and stock price data, please visit
http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact
Sheet about Callisto, please visit
http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an
informational presentation of the Company`s development pipeline of
drug candidates, visit
http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto
is also listed on the Frankfurt Stock Exchange under the ticker symbol
CA4. For additional information, visit www.callistopharma.com.

[conejo2222]

noch mehr news: (und keiner will ueber die aktie reden... ihr werdet euch noch wundernç
Callisto Pharmaceuticals to Profile Key Drug Development Achievements at BIO-Europe 2005 Investor Conference in Germany; CEO Dr. Gary Jacob to Highlight Progress on New Anti-Cancer Drugs, Biowarfare Vaccines and Other Technologies



NEW YORK--(BUSINESS WIRE)--Nov. 3, 2005--Callisto Pharmaceuticals, Inc. (AMEX: KAL) (FWB: CA4), a developer of new drug treatments in the fight against hematological cancers and other diseases and afflictions, will present its clinical and business milestones at BIO-Europe 2005, a high-profile international investment conference designed to bring together key European institutional investors and other leading biotechnology industry figures, in Dresden, Germany, next week.

Selected biotechnology companies interested in partnering technologies or products, co-marketing arrangements, or tapping into the European financing network will present at BIO-Europe 2005, scheduled to take place November 7-9 at the International Congress Center in Dresden. Callisto Pharmaceuticals CEO Dr. Gary S. Jacob will provide a corporate overview to highlight the Company`s intellectual property portfolio and development pipeline of new drug candidates. His presentation is scheduled to begin at 5:15 p.m., in Room #2, Level 4.

"I am looking forward to the broad exposure to European-based institutional investors and others this conference will enable for Callisto," said Dr. Jacob. "We have made important strides in moving forward with our drugs in development for currently incurable blood cancers such as multiple myeloma and relapsed leukemia. Meanwhile, a key element of our strategic vision for growth is the identification of promising in-licensing opportunities to extend our IP portfolio with new drug technologies that present significant potential revenue opportunities."

Callisto is currently focused on several clinical and drug development programs, including the drug candidates Atiprimod and L-Annamycin. Atiprimod is being developed as a treatment for the hematological cancer multiple myeloma, and L-Annamycin is being developed to treat two forms of relapsed leukemia. Callisto`s development pipeline also includes a drug to treat inflammatory bowel disease, as well as a homeland defense initiative called the Superantigen Biodefense Project, which is exploring development of a drug and vaccine to protect against biowarfare agents from the class of Staphylococcus and Streptococcus pathogens.

Last year, 188 companies were selected to present to an audience that included representatives from over 120 pharmaceutical companies and close to 70 financial institutions.

About Bio-Europe 2005

The annual conference is Europe`s largest and most successful partnering conference. It provides a forum where international decision makers in the biotechnology, pharmaceutical, and financial sector can meet to initiate or develop partnerships among their companies. For more information, visit http://www.ebdgroup.com/bioeurope.

[factinvest]

will schon über callisto reden. wie bist du denn hier reingekommen. Über Aktionär? finde callisto ganz gut. Hab allerdings auch schon einiges mitgemacht. Kauf um die 0,90. rauf auf 1,22 runter in die 0,80 gegend dann wieder hoch auf 1,28 und jetzt um den Euro. weisst du conejo was die überhaupt genau machen. Irgendwie nen mix aus nano und biotechnologie, oder?

[conejo2222]

Über Callisto Pharmaceuticals, Inc.

Callisto ist ein biopharmazeutisches Unternehmen, das innovative Krebsmedikamente zur Behandlung von Blutkrebs und damit verwandten Erkrankungen entwickelt, einschließlich akute Lymphoblastenleukämie (ALL), akute myeloische Leukämie (AML), rezidivierendes oder refraktäres Plasmozytom und osteolytische Erkrankungen. Callisto verfügt außerdem über Medikamente in der vorklinischen Entwicklung gegen Magendarmentzündungen und zum Schutz gegen Staphylokokken und Streptokokken, die in Bioterrorwaffen vorkommen könnten. Die beiden führenden Krebsmedikamente von Callisto sind Annamycin, ein neuer liposomaler Wirkstoff aus der Familie der Anthracycline mit möglicherweise verminderter Kardiotoxizität, patentierter Liposomenformulierung und dem Potenzial zur Umgehung einer Multi-Medikamenten-Resistenz bei ALL und AML, sowie Atiprimod, ein oraler Small-Molecule-Wirkstoff mit einem potenziell breiten Wirkspektrum, darunter der Eigenschaft zur Proliferationshemmung von Tumorzellen und antiangiogene Wirkung zur Behandlung von rezidivierendem Plasmozytom. Atiprimod wird derzeit in einer klinischen Studie der Phase I/IIa an vier Prüfzentren in den USA bei Patienten mit rezidivierendem oder refraktärem Plasmozytom getestet. Abgesehen von Krebsmedikamenten entwickelt Callisto einen vorklinischen Wirkstoff zur Behandlung eines Reizdarms. Das Unternehmen hat außerdem im Rahmen eines Bioabwehrprojektes umfangreiche Forschungsgelder vom US-amerikanischen National Institute of Allergy and Infectious Diseases (NIAID) erhalten, um einen monoklonalen Antikörper und einen Impfstoff gegen bakterielle Superantigentoxine zu entwickeln. Bakterielle Superantigene gehören zu den tödlichsten Giften, die es gibt, und könnten möglicherweise als Biowaffe verwendet werden. Anlegerinformationen über Callisto mit aktuellen Pressemeldungen und Aktienkursen gibt es unter http://www.trilogy-capital.com/tcp/callisto/. Ein Investor Fact Sheet über Callisto gibt es unter http://www.trilogy-capital.com/tcp/callisto/factsheet.html. Callisto wird unter dem Tickersymbol CA4 an der Frankfurter Wertpapierbörse gehandelt. Mehr Informationen gibt es auf der Unternehmenswebsite unter www.callistopharma.com.

[conejo2222]

Beacon Equity Research sieht in einer Unternehmensanalyse das 12-Monats-Kursziel für die Aktie von Callisto Pharmaceuticals bei 3,10 USD
Wachstumsanlass seien viel versprechende F&E-Programme zur Behandlung von Tumorrezidiven, ulzerativer Kolitis und gegen Bioterror

Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), ein Entwickler neuartiger Arzneimitteltherapien zum Kampf gegen Blutkrebs und andere Erkrankungen und Störungen, meldete heute, dass der Investmentanalyst Beacon Equity Research in einer umfangreichen Auftragsanalyse des Unternehmens das 12-Monats-Kurziel der Aktie von Callisto bei starken 3,10 USD sieht; die Aktie notiert derzeit bei 1,38 USD.

Beacon zitiert eine Reihe von Investmenthighlights in Verbindung mit den Geschäfts- und Finanzaussichten von Callisto, darunter:

-- Mehrere diverse Arzneistoffe im Entwicklungsportfolio - dadurch verteilt sich der Markterfolg von Callisto auf mehrere Produkte bzw. Sektoren.

-- Zwei wichtige Arzneistoffkandidaten haben bereits eine FDA-Zulassung als "Orphan-Drug" - die Produkte sind dadurch gegenüber Konkurrenzprodukten für bis zu sieben Jahre nach ihrer jeweiligen Markteinführung geschützt.

-- Der Schwerpunkt im Bereich Krebsmedikamente liegt auf der Behandlung rezidivierender oder refraktärer Fälle, bei denen andere Therapien versagt haben - Dies entspricht einer intelligenten "Markteinstiegsstrategie", die ebenfalls einen Wettbewerbsvorteil verspricht.

-- Forschung im Bereich Superantigene könnte erfolgreiche Produkte für den zunehmend gewinnträchtigen und neuen Markt für Homeland Security (Heimatschutz) hervorbringen.

Die Analyse von Beacon beschreibt Callisto unter Anderem als "ein neues Biotechnologieunternehmen mit einer klaren Vision der Entwicklung von Medikamenten zur Behandlung verschiedener Arten von Krebs - Leukämie, Plasmozytom und osteolytische Knochenerkrankungen." Zu den Medikamenten gehört ein Wirkstoff gegen rezidivierende oder refraktäre (behandlungsresistente) akute Leukämie mit dem Namen Annamycin und ein weiterer Wirkstoff zur Behandlung eines rezidivierenden oder refraktären Plasmozytoms und von Knochenresorption mit dem Namen Atiprimod.

"Callisto Pharmaceuticals (AMEX:KAL) verfügt über ein interessantes Konzept und außerdem über Grundlagen, die man bei anderen kleinen Pharmaunternehmen im Entwicklungsstadium normalerweise nicht findet", wie Beacon in der Analyse schreibt. "Investoren sollten wissen, dass dieses relativ junge Unternehmen bereits bemerkenswert diversifiziert ist und derzeit mehrere Arzneistoffkandidaten entwickelt."

Dr. Gary S. Jacob, CEO und CSO von Callisto, zeigte sich sehr zufrieden über die starke Einschätzung der Mission und des Geschäftsmodells seines Unternehmens in der Beacon-Analyse.

"Dieser Bericht wird uns sehr dabei unterstützen, unter Anderem die Investoren von der Bedeutung unserer pharmazeutischen Mission und dem Potenzial unserer verschiedenen Produktinnovationen auf dem internationalen Markt zu überzeugen", so Dr. Jacob. "Callisto war zwar Auftraggeber von Beacon, aber wir halten den Bericht für eine objektive, ausgewogene und umfassende Analyse unserer aktuellen Anlagewerte und unserer zukünftigen Möglichkeiten. Wir fühlen uns geehrt durch die erschöpfenden Recherchen, die in dieser gründlichen und bedächtigen Analyse zum Ausdruck kommen. Es ist aber unbedingt zu betonen, dass die Schlussfolgerungen die Ansicht Beacons wiedergibt und nicht notwendigerweise die Erwartungen oder internen Projektionen von Callisto Pharmaceuticals."

Im Bericht heißt es weiter: "Callistos Portfolio verfügt über zwei Anti-Krebs-Arzneimittelkandidaten, Atiprimod und Annamycin. Diese beiden Kandidaten könnten sich eines Tages bei der Behandlung der schlimmsten Formen von Krebs bei Patienten erfolgreich erweisen, die bisher auf keine andere Behandlung ansprechen. So könnten diese innovativen Medikamente eines Tages großen Einfluss auf den Markt für Krebsbehandlungen insgesamt haben, ganz zu schweigen von den Patienten, die die Hoffnung bereits aufgegeben haben und dann in der Lage sein werden, ihren Kampf gegen die Krankheit mithilfe dieser wirkungsvollen Behandlungen fortzusetzen."

In anderen Entwicklungsprogrammen arbeitet Callisto an der Entwicklung monoklonaler Antikörper und Peptide, die eine unkontrollierte Aktivierung von T-Zellen durch verschiedenste Bakterientoxine oder Superantigene verhindern könnten. Callisto untersucht derzeit die Entwicklung eines monoklonalen Antikörpers als therapeutisches Mittel zur Behandlung von Zivilpersonen und Militär, die Superantigen-basierten Biowaffen ausgesetzt worden sind.

Callisto sucht außerdem nach einer Behandlung gegen ulzerative Kolitis, einer schweren Krankheit, die in der inneren Wand von Kolon und Rektum Geschwüre und Reizungen verursacht. "In den USA, wo 500.000 Menschen an ulzerativer Kolitis leiden, liegt der Marktwert des Produktes bei etwa 800 Mio USD", stellt der Bericht fest.

Callisto hat Beacon beauftragt, einen glaubwürdigen, umfassenden und objektiven externen Forschungsbericht zu erstellen und die resultierende Analyse und Bewertung ist das Ergebnis unabhängiger Arbeit von Beacon. Callisto hat keinen Einfluss auf das Fazit der Analyse oder die Aktienkursprognosen. Der Bericht, der unter den unten beschriebenen Honorarvereinbarungen verfasst worden ist, steht im Internet unter http://www.beaconequityresearch.com/ zur Verfügung.

Über Beacon Equity Research

Beacon Equity Research verpflichtet sich zu Erstellung von Investmentanalysen höchster Qualität, um Investoren dabei zu helfen, informierte Entscheidungen zu reffen. Unser Schwerpunkt liegt überwiegend auf dem unterrepräsentierten Small-Cap-Markt, der von Wall Street Anlegern traditionell gemieden wird. Wir unterhalten keine Investmentbanking oder Beratungskontakte mit den Unternehmen, die wir analysieren, so dass im Gegensatz zu anderen Analystenfirmen keine Interessenkonflikte entstehen. Die von uns vorgestellten Unternehmen haben sich bereit erklärt, über einen vereinbarten Zeitraum hinweg an unserem Analyseprogramm teilzunehmen, und haben außerdem der Bezahlung eines Vorabhonorars zur Deckung von Kosten in Verbindung mit Recherche, Veröffentlichung und Verteilung zugestimmt. Unsere Analyse und unsere Schlussfolgerungen sind daher unbeeinflusst von externem Druck. Unser Ziel ist es, jeden vorhandenen Aspekt des Geschäfts eines Unternehmens auszuloten und den Investoren eine umfassende Beschreibung der möglichen Risiken und Gewinne in Verbindung mit der Aktie eines Unternehmens zu geben. Unsere Berichte werden grundsätzlich von einem Chartered Financial Analyst (CFA) mitverfasst und geprüft. CFA-Spezialisten gehören zu den angesehensten Experten in der Börsenbranche. Durch ihre CFA-Zulassung sind unsere Analysten an den AIMR-Ethikkodex gebunden.

[suncomesout]

DAS nenn ich wertvolle Information:
Die Analysten von Stanford Research bewerten in ihrer Analyse vom Freitag, 22. April 2005 die Aktie von Callisto Pharmaceuticals Inc. neu mit dem Rating " Buy" . Das Kursziel für die Aktie liegt momentan bei 5 $.


Leute, lasst Euch nicht vera....

SCO

[longlongwau]

Amex




Back to Headlines | Previous Story



Join the CEOs of 17 Small Cap Companies Early This Saturday Morning, December 3rd at the SCIA - Southern California Investment Association`s National Investment Conference in Irvine, CA



MONARCH BEACH, CA -- (MARKET WIRE) -- 11/28/05 -- Join this conference for under-recognized opportunities December 3rd from 7:15 a.m. to 2 p.m. at the Orange County Airport Hilton, 18800 MacArthur Boulevard, Irvine, CA 92612, located across from the John Wayne Airport, (SNA). Seating is qualified and limited; register at: www.sciaonline.org.

Conference Presenters: Companies promoting opportunities every 15 minutes after the breakfast reception are: (1) Aeolus Pharmaceuticals, Inc. (OTC BB: AOLS) Small Molecule Catalytic Antioxidants Therapeutics; (2) Bayou City Exploration, Inc. (OTC BB: BYCX) Recovery of New Oil & Gas Reserves in Proven Trends; (3) Bluegrass Partners I, LLC, Tax Advantage Income Oil/Natural Gas Products; (4) Callisto Pharmaceuticals, Inc. (AMEX: KAL) Innovative Therapeutic Intervention Products; (5) Catalyst Lighting (OTC BB: CYSL) Aggressive Security Outdoor Lighting Company; (6) Dermisonics, Inc. (OTC BB: DMSI) Heavy Molecular Drug Transdermal Patch Technology; (7) Global e-Point, Inc. (NASDAQ: GEPT) Encrypted Wireless Network Surveillance Systems; (8) Global Food Technologies, Inc., pre-AMEX (www.globalfoodtech.com) Patented Method to "Kill" Food-Borne Pathogen; (9) Luminart Corp. (OTC: LUMP) Custom Gel Lit Media Sign Machines & Products; (10) Natural Gas Producers, LLC, Unconventional Exploration & Production Areas of Oil & Gas; (11) Navitone Technologies, Inc. (OTC BB: NVTN) Software Solution Provider & Services in Asia & North America; (12) Osage Energy Company, LLC, pre-merger from San Francisco, (13) Paxton Energy, Inc. (OTC: PXTE) North American Oil & Gas Investment Partnerships; (14) Petro Resources Corporation (OTC: PRCT) Independent Domestic Oil & Gas Exploration & Production; (15) Prospect Medical Holdings (AMEX: PZZ) Management Services Primarily to Affiliated IPAs; (16) Sense Holdings, Inc. (OTC BB: SEHO) Homeland Security Biometric/Micro-Sensor Solutions; (17) pre-merger U.S. Dry Cleaning Corporation, Retail Consolidator Focused on Higher Returns headquartered in Los Angeles.

Morning Agenda: See Conference Presentation Schedule: https://www.sciaonline.org/Feb05Schedule44304.pdf

About Southern California Investment Association:

SCIA National Small Cap Syndicate is a comprehensive national organization developed to facilitate stock support and capital formation for small to medium listed and emerging-growth companies. The alliance consists of almost 200 member firms and associates including NASD broker/ dealers, investment and merchant bankers, investment advisors, analysts, market makers, venture capitalists, fund managers, media and accredited investors. This team provides a wide range of services including, but not limited to equity and debt financing, stock support, market making, mergers and acquisitions and corporate security strategies.

SCIA presents over 100 companies yearly to a qualified audience on Saturdays mornings, bi-monthly and is known to be the best in class and value offered to small cap companies on the street today. Companies desiring support or funding are encouraged to apply at least one month in advance. The conference schedule for 2006 is February 4th, April 1st, June 3rd, August 5th, October 7th and December 2nd.

SCIA Conference Sponsors: Paulson Investment Company, Inc., The Largest Independent Brokerage Firm in the Pacific N.W., www.paulsoninvestment.com;Preston Gates & Ellis LLP, Law Firm Committed to Diversity, www.prestongates.com; Continental Stock Transfer & Trust Co., Great Value with Flawless Executions, www.continentalstock.com; J. M. Dutton & Associates, LLC, One of The U.S.`s Largest Issuers-Paid Equity Research Firm, www.jmdutton.com; Trilogy Capital Partners, Inc., Effective Financial & Communications Partner with Companies to Reach Full Market Value, www.trilogy-capital.com, Weinberg & Company, P.A., CPA Firm Servicing Small-Middle Market Public Companies, www.cpaweinberg.com; Securities Compliance Control, LLC, Corporate SEC Compliance Consultants, Trymetris Capital Management, LLC, Micro & Small Equity Hedge Fund; Centale, Inc., Direct Response/Sales/Marketing/Software Solution, www.centale.com; Richardson & Patel LLP, Securities Law and Corporate Finance, www.richardsonpatel.com and Value Leader, Market Wire, www.marketwire.com.

Cherry Kau
CEO
949-922-3003
Email Contact

[lonesome loser]

Callisto Announces Newly Allowed Patent on First-in-Class Drug for Colon Cancer and Other Diseases; Research Data Supports Drug`s Potential as Revolutionary, Safe, Non-Toxic Preventative for Cancer and Treatment for Gastro-Intestinal Diseases



NEW YORK, Nov 28, 2005 (BUSINESS WIRE) -- -Callisto Pharmaceuticals, Inc. (KAL) , a developer of new drug treatments in the fight against cancer and other major health threats, announced that the U.S. Patent and Trademark Office has given a Notice of Allowance on a patent for a novel drug compound created by Callisto scientists to treat and prevent a variety of inflammatory diseases of the bowel, including colon cancer. The drug is first-in-class of a new category of compounds with the potential to revolutionize therapy for gastro-intestinal disease, while presenting virtually no known side effects or toxicity.

The Callisto drug candidate, currently known by its laboratory name SP304, is an orally deliverable compound designed to mimic a naturally-occurring hormone called uroguanylin, which is normally produced in the body`s intestinal tract. People with colon cancer lack sufficient quantities of uroguanylin, and this deficiency is linked with colon carcinogenesis. SP304 is designed to replace the naturally occurring compound, but with the added advantage of providing greater anti-inflammatory potency and therapeutic effect. Also significantly, because Callisto`s SP304 is a close molecular relative of the naturally occurring hormone, it is anticipated to be virtually non-toxic.



"Research in animal models has indicated that this new class of compounds and therapeutic approach, represented by Callisto`s drug SP304, has the potential to genuinely revolutionize the treatment of certain very serious inflammatory bowel diseases, as well as colon cancer," said Dr. Gary S. Jacob, CEO and CSO of Callisto. "The science behind SP304 is an exciting new avenue in cancer and anti-inflammatory treatment research, and Callisto is proud to be the first to patent a drug in this groundbreaking, next-generation category of potential therapies."

Callisto`s SP304 drug candidate is designed to help replenish damaged cells in the lining of the colon -- cells that may become cancerous -- to function as therapies for people who have gastro-intestinal diseases such as ulcerative colitis or colon cancer. It also is being evaluated as a preventative measure to stop cancer and other diseases from developing.

One of the major physiological functions of uroguanylin is the regulation of cell health in the colon lining, including the elimination of mutated cells and the replenishment of healthy cells. "This delicate balance of elimination and renewal of the cells of the colon lining is crucial to the prevention of cancer. We believe SP304 can be an effective oral therapy to prevent benign colorectal polyps from becoming cancerous," said Dr. Kunwar Shailubhai, Senior Vice President, Discovery Research for Callisto, who is one of the drug`s inventors. "Research data has also shown the drug to have very impressive anti-inflammatory properties, suggesting it is an excellent candidate as a treatment for inflammatory bowel diseases such as ulcerative colitis."

More than 500,000 Americans are afflicted with ulcerative colitis, a type of inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract. Along with Crohn`s disease, the other major form of IBD, ulcerative colitis can be painful and debilitating, and can lead to other serious and life-threatening complications. There is currently no medical cure for ulcerative colitis.

Colon cancer, also called colorectal cancer, is the second leading cause of cancer death among men and women in the United States and Canada, and is the third most diagnosed cancer, excluding skin cancer. The American Cancer Society estimates that there will be 146,940 new cases of colorectal cancer diagnosed in the U.S. in 2004 -- roughly one new case every 4 minutes. Although colon cancer can be treated through surgery, chemotherapy and radiation, currently there are no drugs specifically designed for its prevention and treatment.

The Notice of Allowance for Callisto`s SP304 was given for the patent titled, "Guanylate Cyclase Receptor Agonists for the Treatment of Tissue Inflammation and Carcinogenesis." The USPTO has allowed key claims covering the composition of matter of the SP304 compound; additional claims are pending in divisional applications.

"This patent allowance is a scientific and strategic milestone for Callisto that further strengthens our pipeline of significant drug technologies and our mission to develop needed new medical treatments," added Dr. Jacob.

[longlongwau]

StockConsultant
Enter Symbol




After Hours News



AfterHours news for LargeCap stocks could present traders something to watch in the morning. The following "Top Stories" were issued after the bell.



KAL: Newly Allowed Patent on First-in-Class Drug for Colon Cancer and Other Diseases

[longlongwau]

Callisto Anti-Cancer Drug Atiprimod Chosen for Second High-Profile Oral Presentation at American Society of Hematology Meeting; Newly Released Research Paper Details Anti-Tumor Activity of Atiprimod in Animal Study



NEW YORK--(BUSINESS WIRE)--Nov. 29, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other serious health threats, today announced that its anti-cancer drug candidate Atiprimod has been further recognized by the scientific community with selection for a second Oral presentation of research data, abstract (#249), at the annual meeting of American Society of Hematology (ASH), the field`s most important scientific organization, to be held next month in Atlanta, GA.

Callisto`s research collaborators at Dana-Farber Cancer Institute will present findings of an animal-based study to investigate the effect of Atiprimod on multiple myeloma tumors, a serious, currently incurable form of blood cancer. The animal study, conducted by researchers at Dana-Farber, observed that Atiprimod produced experimentally significant reduction in tumor levels.

"Callisto is pleased to have a second abstract dealing with Atiprimod chosen for oral presentation at the ASH annual meeting," said Dr. Gary S. Jacob, CEO and Chief Scientific Officer of Callisto. "This second paper deals with Atiprimod`s anti-tumor activity in elegant models of multiple myeloma developed by researchers at Dana-Farber, as well as evaluation of genes that are affected in multiple myeloma cells exposed to the drug. The Atiprimod findings are very encouraging, and we are gratified again that our peers in the scientific community have deemed this research worthy of the particular notice made possible by this oral presentation at the ASH conference."

The newly-announced oral presentation at the ASH meeting will cover not only information released in the abstract (#249), but additional research data obtained subsequent to submission of the abstract. The entire abstract is now available on the ASH Web site, www.hematology.org. The meeting is scheduled for December 10-13, 2005, in Atlanta, Georgia. The oral presentation will be delivered at 8:00 am on Monday, December 12, in the Sidney Marcus Room of the World Congress Center in Atlanta, GA, by Dr. Paola Neri of the Dana-Farber Cancer Institute. It is entitled: "In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma."

Callisto previously announced that a separate oral presentation dealing with the results from the Phase I/IIa clinical trial of Atiprimod in refractory or relapsed multiple myeloma patients will be delivered at 5 pm on December 11, in an Oral Session entitled: "Multiple Myeloma: Novel Therapeutic Approaches" in the Sidney Marcus Room of the World Congress Center in Atlanta, GA.

The newly-announced abstract, #249, describes Atiprimod`s activity in three mouse models of human multiple myeloma in addition to gene expression profiling data observed on cells exposed to Atiprimod. One of the animal models evaluated the effect of Atiprimod on human multiple myeloma cells in a human bone marrow microenvironment. In this model, mice were implanted with a human fetal bone chip engrafted with multiple myeloma cells and treated i.p. with Atiprimod (40 mg/kg) or vehicle alone (PBS) for two weeks. The researchers observed a 60% reduction in the indicator of anti-tumor activity in mice treated with Atiprimod versus control group. To evaluate effects of Atiprimod on primary patient cells in a human microenvironment, mice were engrafted with patient multiple myeloma cells (IgG gamma) and treated i.p. with Atiprimod (50 mg/kg) or vehicle alone (PBS) for 4 weeks. Treatment with Atiprimod induced a reduction in both human IgG and gamma light chain levels in mouse sera, whereas levels of both proteins continued to rise in mice treated with vehicle alone. The molecular changes in multiple myeloma cells induced by Atiprimod were also evaluated using gene expression profiling of multiple myeloma cells exposed to Atiprimod. Atiprimod induced significant down-regulation of genes involved in growth and cell-cycle control, adhesion, cell-signalling pathways, up-regulation of genes implicated in apoptotic cascades and in negative regulation of signal transduction.

About the American Society of Hematology

The mission of the American Society of Hematology (ASH) is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. For the past four decades, ASH has sponsored its annual meeting, the premier annual education and scientific event in the field of hematology, and has published Blood, the Journal of the American Society of Hematology, which is the most cited peer-reviewed publication in the field. Each December, the Society`s annual meeting provides hematologists from around the world a forum for discussing critical issues in hematology. Nearly 20,000 clinicians, scientists, and others attend the four-day meeting, which consists of a superb educational program and cutting-edge scientific sessions. Oral and poster presentations, which are chosen by peer-reviewers from abstracts submitted prior to the annual meeting, are featured at the annual meeting and contain the latest and most exciting developments in scientific research. For more information, please visit http://www.hematology.org.

About Callisto Pharmaceuticals, Inc.


Callisto is a biopharmaceutical company focused on the development
of new drugs to treat various forms of cancer and other serious
afflictions. Callisto`s drug candidates in development currently
include anti-cancer agents in clinical development, in addition to
drugs for a range of other significant health care market segments,
including biodefense. One of the Company`s lead drug candidates,
L-Annamycin, is being developed as a treatment for forms of relapsed
leukemia, a currently incurable blood cancer. Callisto intends to
initiate a clinical trial of L-Annamycin in relapsed acute
lymphoblastic leukemia patients in 4Q 2005. L-Annamycin, a new
compound from the anthracycline family of proven anti-cancer drugs,
has a novel therapeutic profile, including activity against resistant
diseases and significantly reduced cardiotoxicity, or damage to the
heart, compared to currently available drug alternatives. Another
anti-cancer drug, Atiprimod, is in development to treat relapsed
multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa
human clinical trials in relapsed multiple myeloma patients. Callisto
also has drugs in preclinical development for gastrointestinal
inflammation, and a program focused on the development of a drug to
protect against staphylococcus and streptococcus biowarfare agents.
Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D.
Anderson Cancer Center to develop, manufacture, use and sell Atiprimod
and L-Annamycin, respectively. For investor-specific information about
Callisto, including recent news and stock price data, please visit
http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact
Sheet about Callisto, please visit
http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an
informational presentation of the Company`s development pipeline of
drug candidates, visit
http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto
is also listed on the Frankfurt Stock Exchange under the ticker symbol
CA4. For additional information, visit www.callistopharma.com.


Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.


CONTACT: Callisto Pharmaceuticals, Inc.
Dan D`Agostino, 212-297-0010 x227
[e-mail]
or
Trilogy Capital Partners, Inc.
Paul Karon, 800-592-6067 (Investor Relations)
[e-mail]

SOURCE: Callisto Pharmaceuticals, Inc.

[longlongwau]

Callisto Pharmaceuticals` Biodefense Development Program Selected for Presentation at Leading Scientific Conference; Company to Present Recent Research at Late Breaker Session of Interscience Conference of Antimicrobial Agents and Chemotherapy



NEW YORK--(BUSINESS WIRE)--Nov. 30, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other serious healthcare threats, today announced that the Company`s biodefense research program has been selected for a presentation in the "Late-Breaker Research Session" of the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), a high-profile international meeting to be held from December 16th to 19th, 2005, at the Washington, DC, Convention Center.

Callisto is involved in a joint biodefense program with the U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, and The Rockefeller University, New York, NY, to investigate and develop vaccines and treatments for use in bio-warfare applications. The Company will provide a poster presentation of an abstract about its research into the efficacy of antibodies and peptides as drug candidates to counter some of the most potentially lethal, viable and easily weaponized bio-warfare toxins. Callisto`s poster is scheduled for presentation at 10 a.m. on December 17th at the Convention Center in Washington, DC, in Hall B.

The ICAAC meeting is co-sponsored with the American Society for Microbiology (ASM), and it is one of the world`s leading scientific and educational forums for researchers and health care professionals working to foster worldwide solutions to the problem of infectious disease. Late-breaking abstracts go through a strict review process and must reflect novel research findings, according to ICAAC.

"The acceptance of Callisto`s research abstract by the ICAAC program committee is a reflection of the importance and relevance of our work to the global fight against the threat of bioterrorism and biowarfare," said Dr. Gary S. Jacob, CEO and Chief Scientific Officer of Callisto. "This presentation represents a high-profile opportunity for Callisto and our development partners to cast a national spotlight on our efforts to develop new vaccines, therapies and diagnostic tools to protect our military forces and the public."

Callisto`s conference presentation will focus on its work to develop monoclonal antibodies designed to act as broad-spectrum antidotes against the superantigen biowarfare toxins derived from staphylococcus and streptococcus pathogens, said Dr. Kunwar Shailubhai, Senior Vice President of Drug Discovery at Callisto, and the presenting author of the abstract presentation. "These toxins are easy to weaponize in aerosol formulations using very simple tools in simple laboratories," said Dr. Shailubhai. "Thus, there is an urgent, unmet need to develop broad-spectrum countermeasures to these and other looming biological threats, and we believe our program can play a key role in the creation of effective and critically needed new drug treatments against viable biological warfare and terrorist weapons."

Dr. Shailubhai will present the abstract with strategic development partners and co-authors from The Rockefeller University in New York and at the Army Medical Research Institute for Infectious Diseases (USAMRIID) in Fort Detrick, MD. Entitled, "Broad-Spectrum Protection Against Superantigen Toxins by an Antagonist Peptide and a Monoclonal Antibody," this paper will shed light on their joint efforts to fight a particularly incapacitating and lethal toxin, called staphylococcus aureus B.

Dr. Shailubhai also has joint appointments as a professor at the Institute for Hepatitis and Viral Research (IHVR) and as an adjunct Professor at the Drexel Center for Biotechnology and Virology Research (DIBVIR), where he directs research into "Peptide and Antibodies as Antidotes for Superantigens," as part of Callisto`s joint development program. That research is being funded in part by a major grant of $885,000 from the National Institute of Allergy and Infectious Diseases (NIAID).

For more information about the ICAAC, please visit http://www.icaac.org/default.asp.

[longlongwau]

SmallCap Sentinel: Patents, Cancer Drugs and Knowing Who Has the Goods
IRVINE, Calif., Dec. 1, 2005 (PRIMEZONE) -- "Recent announcements by biotechnology firms related to the development of new treatments and cures for cancer have stoked interest in biotechnology," stated SmallCap Sentinel analyst, D.R. Clark. "Few things resonate more with the investing public than technology that addresses one of our true mortal fears in cancer. The problem- for investors- has always been in discerning which companies truly have something special in development."

"A first step in separating biotech wheat from chaff is patent approval," Clark added. "Most start-ups will never get that far though their early press releases and headlines will sing the likelihood of some future cure-all.," Clark added. "Getting to the patent stage is an entirely different and often unattainable benchmark."

"For example, Callisto Pharmaceutical`s (AMEX:KAL) announcement that the U.S. Patent and Trademark Office has given a Notice of Allowance on a patent for a drug compound created by their scientists to treat and prevent a variety of inflammatory diseases of the bowel such as colon cancer signals a real milestone for that company," Clark added. "This doesn`t happen everyday, let alone for mid-size firms like Callisto."

Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.

The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at:

[factinvest]

Hi hab gedacht ich beteilighe mich an deinem monolog mal. Sieht nicht schlecht aus. Hab mir das ding bei 0,91 nach empfehlung in der aktionär geholt. wie bist du drauf gekommen. wir schiessen demnächst die decke raus.

[longlongwau]

hallo, ist ja erfreulich, dass ausser mira uch noch einer die aktien hat

ich denke, dass bei weiterhin guter nachrichtenlage, die aktie kontinuierlich steigen duerfte. ruecksetzer nicht ausgeschlossen. leider hatte ich bei 0,88 cent letzte woche kein cash....

auf jeden fall zum nachkaufen nutzen..

hat hier noch jemand aktien von callisto??

gruesse

[lonesome loser]

Friday December 2, 4:01 PM EST


NEW YORK, Dec 02, 2005 (BUSINESS WIRE) -- Callisto Pharmaceuticals, Inc. (KAL) , a developer of new drug treatments in the fight against cancer and other serious healthcare threats, today announced that equity analysis firm EquityNet Research has initiated paid research coverage of the Company with a detailed report that recommends a "Buy" rating, and projects a 12-month share price target of $3.45.

In determining its projected share price appreciation for Callisto, EquityNet noted a number of core growth factors, including the Company`s diverse and unique intellectual property portfolio. This currently includes Callisto`s multiple drug development programs for new and needed cancer treatments, a biodefense Homeland Security program, and a proprietary drug for gastro-intestinal inflammation. The report also cited Management`s strategic vision to continue to expand its development pipeline through development and acquisition of potential high-revenue drug technologies and candidates.



"Rather than a typical fledgling biopharmaceutical company, we see KAL as a bona-fide drug development concern, one that has great leadership and alignment with top-notch scientific community institutions and members," wrote EquityNet Research analyst Randy D. Lewis, CFA. "The cancer treatment market is hungry for new, more successful treatments, and should the Company prove efficacy in any of many indications, future earnings performance should be outstanding."

Callisto`s R&D diversity is one of its key competitive advantages, because this multi-pronged development strategy reduces dependence on any one drug or market segment for its success, according to the EquityNet Research report. Callisto has also increased efforts to identify promising in-licensing opportunities to extend its IP portfolio with new drug candidates that present potential high-growth revenue opportunities.

Callisto`s two lead anti-cancer drug candidates, Atiprimod and L-Annamycin, are being developed respectively to treat multiple myeloma and two forms of relapsed leukemia. The Company is also developing a drug to treat inflammatory bowel disease, and has a novel homeland defense initiative termed the Superantigen Biodefense Project, which is exploring development of a drug and vaccine to protect against biowarfare agents from the class of Staphylococcus and Streptococcus pathogens.

Additional competitive advantages described in the report include:

-- Minimizing Competition: The Company`s initial focus has been on smaller markets that the big Pharmas don`t traditionally pursue, such as treatments for relapsed or refractory cases of cancer, potentially minimizing competition and eliminating the need to go head-to-head with larger industry players.

-- Marketing Exclusivity Protection: The FDA`s designation of "orphan drug" status for two of Callisto`s drug candidates provides market exclusivity and other advantages.

-- Revolutionary Drug Development: Callisto has received patent protection for its drug SP304, a first-in-class drug candidate for the treatment of ulcerative colitis, a frequently devastating gastro-intestinal inflammatory disease.

-- Homeland Security Market Opportunity: The biodefense aspect of the Company`s model provides additional large market and diversification benefits, as well as speculative appeal.

CEO and Chief Scientific Officer, Dr. Gary S. Jacob said, "Callisto has engaged EquityNet Research to conduct a thorough, responsibly researched and credible analysis of Callisto and the market. Though it is paid research, we believe the EquityNet report presents an engaging, balanced and detailed view of our company and its new drug candidates in development to treat a wide range of diseases and conditions."

Callisto has compensated EquityNet Research to conduct a comprehensive and objective third party research report, and the resulting analysis and assessment is EquityNet`s own independent work product. Callisto did not participate in the creation of the conclusions in the report, nor its price growth projections.

[mobilepro]

bin gespannt auf heute

[factinvest]

Hi sagte doch dass wir demnächst die decke raus schießen. Hab läuten hören dass am Freitag nach Börsenschluss Kursziel von 3,45 $ von eqity research ausgegeben worden ist. Kann es aber nicht garantiern dass es stimmt. weiss da einer was drüber. Egal dass ding macht die 2$ diese woche noch klar.

[lonesome loser]

LOS ANGELES, Dec 06, 2005 (BUSINESS WIRE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today a newly available interview with Dr. Gary S. Jacob, CEO and CSO of Callisto Pharmaceuticals, Inc. (KAL) . In the interview, Dr. Jacob provides fresh insight and discussion about the start of the recently launched clinical trial of the Company`s drug candidate L-Annamycin, which the Company is developing as a treatment for patients with relapsed or refractory acute lymphocytic leukemia (ALL).

In the interview, Dr. Jacob explains the newly launched adult clinical trials of L-Annamycin at The University of Texas M. D. Anderson Cancer Center in Houston, Texas, widely considered one the world`s leading health care institutions for cancer treatment and research. The first patient with refractory or relapsed ALL entered the Phase I/II trial on December 1, 2005, under the direction of principal investigator Dr. Hagop Kantarjian, Chairman of the Department of Leukemia, and a leader in the field of leukemia.



Dr. Jacob said L-Annamycin has shown promise as a potential life-saving treatment alternative for some of the most desperately ill leukemia patients.

L-Annamycin is a member of an already proven class of anti-cancer drugs, but presents a novel therapeutic profile, including indications of effectiveness on multi-drug-resistant tumors. This feature is what may enable L-Annamycin to be used as a treatment for so-called relapsed patients, or patients who have stopped responding positively to all available drug treatments, and have few or no options for further treatment. The drug has also demonstrated indications of a substantially reduced cardiotoxic effect, or toxicity to the heart, compared with other common anti-cancer drugs.

In previous studies, L-Annamycin has demonstrated encouraging therapeutic results in preclinical and human clinical trials as a potentially viable treatment for not only ALL but for another form of leukemia, acute myelogenous leukemia (AML). This devastating and usually terminal blood and bone marrow disease is the more common type of leukemia in adults, with more than 10,000 new cases diagnosed annually. L-Annamycin is being developed as a treatment for both ALL and AML.

[lonesome loser]

NEW YORK, Dec 05, 2005 (BUSINESS WIRE) -- Callisto Pharmaceuticals, Inc. (KAL) , a developer of new drug treatments in the fight against cancer and other major health threats, announced today its milestone launching of the first clinical trial of an innovative new drug candidate, liposomal Annamycin (L-Annamycin), for the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in adult patients.

Start of the human trial of L-Annamycin is a critical step in Callisto`s efforts to bring this proprietary drug to the marketplace. Patients with relapsed or refractory ALL typically develop cancer cells that are resistant to the currently-approved drugs, and are therefore in desperate need of a drug that overcomes this resistance. The trial is the first time researchers will be able to test the drug on a significant population of adult patients with difficult-to-treat relapsed or refractory cases of acute lymphocytic leukemia.



The trial is being launched at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. The first patient with refractory or relapsed ALL entered the Phase I/II trial on December 1, 2005, under the direction of Dr. Hagop Kantarjian, the principal investigator at M. D. Anderson Cancer Center. Dr. Kantarjian is Chairman of the Department of Leukemia, and a highly respected leader in the field of leukemia.

"We are extremely pleased to see this trial get underway," said Dr. Gary S. Jacob, CEO and CSO of Callisto. "There is a huge unmet need for new agents to treat adult patients with relapsed and refractory forms of acute lymphocytic leukemia. L-Annamycin is a next-generation drug with the potential to work in these patients who have become resistant to other drugs. We hope that further demonstrations of L-Annamycin`s efficacy and safety will pave the way to rapid approval of this drug for the tens of thousands of ALL patients worldwide whose condition is worsening."

This single-arm, open-label L-Annamycin trial is designed to enroll approximately 12 patients in the dose escalation Phase I portion and, subsequently, 10 patients at a final fixed dose in the Phase II portion. Up to 34 adult patients will be treated in this single-arm trial; many of these patients will be treated at M. D. Anderson Cancer Center. L-Annamycin is administered by infusion using a unique patented liposomal formulation.

In previous published animal studies, L-Annamycin has demonstrated that it can kill tumor cells that are resistant to other anthracycline drugs. In addition, earlier studies have shown that L-Annamycin may have other key advantages over other anthracycline drugs, including a decreased risk of treatment-related cardiomyopathy (inflammation of the heart muscle)

Callisto additionally plans to evaluate L-Annamycin for the treatment of children with refractory or relapsed ALL, and refractory or relapsed acute myelogenous leukemia (AML), respectively, as well as in the treatment of adults with relapsed or refractory AML in combination with Ara-C. Callisto intends to begin separate clinical trials in these populations in the next several months. If these trials are successful, an even broader population of leukemia patients could benefit from L-Annamycin.

Recently, the FDA granted L-Annamycin "orphan drug" designation for the treatment of both ALL and AML. This designation guarantees that after FDA approval of the drug, the sponsoring company has marketing exclusivity within the United States for seven years following commercial launch. The FDA`s Orphan drug designation also provides significant additional benefits to the sponsoring company, including eligibility for research grants and protocol assistance, opportunities for regulatory agency assistance on review of clinical protocols, and waiver of the Prescription Drug User Fee Act (PDUFA) filing fee.

Callisto has an exclusive worldwide license from The University of Texas M. D. Anderson Cancer Center to develop, manufacture, use and sell L-Annamycin worldwide.

[longlongwau]

so, jetzt kommt halt drauf an, ob die am menschen gestesten medikamente auch wirklich helfen... hoffentlich gehts nicht so wie bei NABI. da hats nicht geklappt und die sind von einem tag auf den anderen 72% einbegrochen. hoffen wir mal das beste....

[factinvest]

Ja dass wär sch... lecht. Aber wenn die Medikamente helfen machen wir mehr als 72 % gewinn. Dann geht die post ab. Also hoffen. Wobei callisto nicht nur ein medikament hat und so das risiko gestreút wird.

[longlongwau]

die nabi haben auch mehrere in der pipeline... aber ich glaube auch mehr an callisto, als an nabi, obwohl ich heute mal ein paar gekauft habe, da ich an einen rebound glaube. callisto kann durch nochmal bis auf 90 euro cent fallen. dann werde ich nochmal nachkaufen...

[lonesome loser]

NEW YORK, Dec 08, 2005 (BUSINESS WIRE) -- Callisto Pharmaceuticals, Inc. (KAL) , a developer of new drug treatments in the fight against cancer and other major health threats, today announced the availability of a streaming audio interview given by CEO and Chief Scientific Officer Dr. Gary S. Jacob to the online investor news and information source, the Wall Street Reporter.

In the interview, Dr. Jacob outlines the Company`s scientific achievements and its multi-pronged R&D program.

Callisto`s drug development pipeline and intellectual property portfolio currently includes new drugs in development for the blood cancers leukemia and multiple myeloma, as well as a biodefense program to develop vaccines for the Homeland Security marketplace, and a proprietary breakthrough drug candidate for a variety of serious gastro-intestinal conditions.



Callisto`s drugs Atiprimod and L-Annamycin are currently in clinical trials, and are being developed as treatments for patients with relapsed cases of multiple myeloma and acute leukemias, respectively.

L-Annamycin and Atiprimod could eventually provide a new clinical standard of care for relapsed patients whose cancers don`t respond under the currently available regimens, Dr. Jacob says in the interview. He also notes that Atiprimod recently was recognized by the scientific research community: two separate research abstracts on the drug were selected as the subject of high-profile oral presentations for delivery, and one abstract was selected as a poster presentation later this week at the prestigious, high-profile annual meeting of the American Society of Hematology in Atlanta, Ga., Dec. 10-13.

In addition, Dr. Jacob discusses the Company`s development of a proprietary drug to treat ulcerative colitis and other serious gastro-intestinal conditions, and that may serve as a preventative therapy for colon cancer. He also provides details of Callisto`s homeland defense initiative, the Superantigen Biodefense Project, which is exploring development of a drug and vaccine to protect against biowarfare agents from the class of Staphylococcus and Streptococcus pathogens, with the aid of a major development grant from the National Institute of Allergy and Infectious Diseases.

[lonesome loser]

NEW YORK, Dec 08, 2005 (BUSINESS WIRE) -- Callisto Pharmaceuticals, Inc. (KAL) , a developer of new drug treatments in the fight against cancer and other major health threats, today announced the formation of a Department of Intellectual Property to spearhead growth of the Company`s pipeline of new drug candidates, while broadening protection of its intellectual property portfolio through creation of multiple patents around broad classes of new drugs, as well as narrowly-focused claims on specific compounds.

Callisto has named Dr. David Ladner, a patent agent and research scientist with extensive background in the pharmaceutical and chemical industries, to head the unit in the position of Director of Intellectual Property.



"The robust expansion of our intellectual property portfolio is a cornerstone of our strategy to maximize Callisto`s revenue potential, and further strengthen our fundamental mission to develop important new medical treatments," said Dr. Gary S. Jacob, CEO and Chief Science Officer of Callisto Pharmaceuticals. "Our strategy is designed to expand as well as aggressively protect our intellectual property assets as our scientific personnel and clinical research programs work to develop new drug treatments."

Callisto is continuing to build its portfolio of drug technologies through in-licensing of new drug compounds that address significant health care needs and markets. Dr. Ladner and Dan D`Agostino, Chief Business Officer for Callisto, will lead M&A and development activities to expand the company`s intellectual property portfolio through the identification and acquisition of promising drug candidates. The Company continues to foster strategic research collaborations with universities and other key research partners with the objective of substantially increasing its portfolio of new drug candidates.

The move to create the new unit comes on the heels of pivotal intellectual property growth at Callisto, including recently announced allowed US patent for a first-in-class, breakthrough drug compound to treat and prevent gastro-intestinal diseases, including colon cancer and ulcerative colitis, a frequently devastating condition in need of more effective medical treatments. Some 500,000 Americans are estimated to have ulcerative colitis, in a market valued at $800 million. Callisto`s drug, currently called SP304, is the first compound in this newly emerging class of treatments to receive patent protection.

In addition, Callisto is developing new antibodies and peptides in a Homeland Defense drug program to create a proprietary class of superantigen technologies to combat biowarfare threats. The Company is developing a drug and vaccine to protect against biowarfare agents from the class of Staphylococcus and Streptococcus pathogens, with the aid of a major development grant from the National Institute of Allergy and Infectious Diseases. These compounds are covered by extensive patent estates, including both `composition-of-matter` and `use` patents. A poster presentation about the Superantigen Biodefense Program will appear in the "Late-Breaker Research Session" at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (control #4024) on December 17, 2005, at 10:00 am, at the Washington, DC Convention Center (ICAAC(TM); http://www.icaac.org/).

Callisto recently announced the launch of adult human clinical trials of a second anti-cancer drug, L-Annamycin, being developed as a treatment for relapsed or refractory acute lymphocytic leukemia.

Dr. Ladner, a longtime senior research scientist with extensive experience as a patent agent and specialist in the chemical and pharmaceutical industries, holds a Ph.D. in Organic Chemistry. He was a manager of Intellectual Property at Bayer Pharmaceutical Division for the last five years, where he handled patent filing and prosecution for Chemical Research. He also served as Patent Liaison as well as Research Manager at American Cyanamid Co., for over 20 years, overseeing key aspects of patents and intellectual property. Dr. Ladner holds 22 patents himself, and has published widely in professional journals.

In the post, Dr. Ladner will oversee a range of matters pertaining to patents, licensing rights and other proprietary technologies for Callisto. "Our mission is to continue to accelerate Callisto`s strategic efforts to develop a broad array of drugs targeting multiple market segments worldwide," said Dr. Ladner. "We anticipate the establishment of new strategic research partnerships and in-licensing initiatives to broaden our portfolio of therapeutic drug candidates."

[longlongwau]

test

[lonesome loser]

Callisto Research Note Issued by Beacon Equity Research, Reiterates Share Price Growth Target of $3.10; Investrend Research Affiliate Cites Recent Milestone Launch of Adult Clinical Trials of L-Annamycin Drug Candidate

[longlongwau]

das ist ein teil einer empfehlung, die aber doch schon etwas laenger zurueckliegt, wenn ich mich nicht irre, oder?

ich habes vorher schonmal geschrieben, als die aktie nbei 1,35 euro waren, das es wieder runtergeht. langsam kommt es dem kurs nahe, den ich fuer neuekauf nutzen will....

auf lange sicht bin ich sehr positiv fuer hbsc. kursfristig sehr volatil, weil auch keien neuigkeiten und press releases kommen...